Northwestern University Feinberg School of Medicine

Department of Dermatology

Clinical Trials

Clinical and Outcomes Research under the direction of the Department of Dermatology is conducted at the Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, and Northwestern Lake Forest Hospital dermatology clinics.

For more information about the research or participation, please call our office at 312-503-5944.

Trials
DERMATOLOGY TISSUE ACQUISITION AND REPOSITORY
Northwestern University’s Department of Dermatology is collecting skin, hair, nail, blood, saliva, skin and/or buccal swabs, and mucous membrane(part of your skin which lines body passages and cavities such as the inside of your mouth or nose), and ot…
Northwestern University’s Department of Dermatology is collecting skin, hair, nail, blood, saliva, skin and/or buccal swabs, and mucous membrane(part of your skin which lines body passages and cavities such as the inside of your mouth or nose), and other tissue samples for use in a biorepository. By operating this biorepository, the Department of Dermatology hopes to develop a better understanding of skin diseases (meaning the knowledge about how cells in the skin behave and react to medical treatments) among researchers at Northwestern University and other approved researchers. This basic knowledge is expected to help the development of more effective patient care and new treatment methods.
-Having specimens collected as part of a standard of care procedure;
-Have a skin disease which researchers want samples of in order to further understand
it; or
-Qualify as a healthy volunteer whose samples researchers can use as control samples
for research.
West, Dennis PWest, Dennis P
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00009443
More Info

For more information on this study please contact us:

Pease, David 312 503 5901
Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis
The aim of this study is to determine if videocapillaroscopy could be used as an objective and reliable method to assess psoriasis severity and to document improvement during treatment by measuring changes in vascular features.…
The aim of this study is to determine if videocapillaroscopy could be used as an objective and reliable method to assess psoriasis severity and to document improvement during treatment by measuring changes in vascular features. Subjects will receive 6 months of either Humira or Methotrexate.
18-75 years old with the diagnosis of moderate-to-severe plaque psoriasis; participants must be willing to have taken digital photographs of their plaque lesions and uninvolved skin; participants must not have not taken any systemic psoriatic therapy for at least 4 weeks before the start of the study and/or use of any topical treatments at least 2 weeks prior to start of the study.
Brieva, Joaquin CBrieva, Joaquin C
NCT02162472 STU00078102
More Info

For more information on this study please contact us:

Ali, Yasmeen 312 503 5906
Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
To evaluate the safety and effectiveness of the topical ointment (cream), SGX301, in combination with light therapy in patients with cutaneous T-cell lymphoma.
Must be 18 years of age or older, with a clinical diagnosis of Cutaneous T- Cell Lymphoma, Myucosis Fungoides, Stage IA. Stage IB, or Stage IIA, and willing to refrain from sunbathing for duration of the study.
Guitart, JoanGuitart, Joan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02448381 STU00200530
More Info

For more information on this study please contact us:

Serrano, Linda 312 503 5903
Observational US Study Assessing Outcomes, Treatment Patterns, AEs, QOL in MF-CTCL Patients and Treated With Valchlor
The purpose of this study is to better understand: the use of Valchlor®; the disease of MF-CTCL; the health outcomes in patients treated with Valchlor® under care by your doctor.
Adult patients currently being treated with Valchlor®, for the treatment of mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL) and able to sign an informed consent form without assistant from others.
Guitart, JoanGuitart, Joan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02296164 STU00200362
More Info

For more information on this study please contact us:

Serrano, Linda 312 503 5903
AAD-PEPR: Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments
The purpose of this study is to validate patient-reported outcomes (PRO) measures in three existing asthma intervention trials as well as a large group of itch-specific pediatric skin conditions, primarily focusing on a…
The purpose of this study is to validate patient-reported outcomes (PRO) measures in three existing asthma intervention trials as well as a large group of itch-specific pediatric skin conditions, primarily focusing on atopic dermatitis (AD, or eczema). The study will look at how well Patient Reported Outcomes Measurement Information System (PROMIS) tools uncover meaningful changes in disease status as well as build a list of items relating to pediatric skin diseases and a PRO model for signs and symptoms of skin disease.
Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00202292
More Info

For more information on this study please contact us:

Zebda, Rema 312 227 6484
A Phase 1 Dose-Ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 following Local Intratumoral and Subcutaneous Injection in Patients with Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-Type
The main goal of this study is to test the safety and tolera…
The main goal of this study is to test the safety and tolerability of multiple injections subcutaneously (under the skin) or an IV infusion of MRG-106, in patients with CTCL, MF subtype.
Diagnosed with CTCL, MF subtype, Stage 1,2 or 3, have at least one lesion that is a raised plaque or tumor, have not had an adequate response to other CTCL therapies, and are capable of self care.
Guitart, JoanGuitart, Joan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02580552 STU00201702
More Info

For more information on this study please contact us:

Serrano, Linda 312 503 5903
Defining the Skin and Blood Biomarkers of Ichthyosis
Ichthyosis is a group of genetic skin disorders that present with dry, thickened, scaly, or flaky skin. As of today, there is no cure or treatment. Doctors can only treat the dry skin with different types of emollients to soften the scale. A deeper…
Ichthyosis is a group of genetic skin disorders that present with dry, thickened, scaly, or flaky skin. As of today, there is no cure or treatment. Doctors can only treat the dry skin with different types of emollients to soften the scale. A deeper understanding of this disease is required to develop better treatments. There are different types of cells and cell-produced signals (biomarkers) that are being studied in order to help find these new treatments. Looking at biomarkers has been successful in helping us to understand other skin disorders better. The purpose of this study is to determine which blood and skin biomarkers characterize ichthyosis in children.
Subjects (1 year to 60 years of age) with Autosomal Recessive Congenital Ichthyosis (ARCI), which includes lamellar Ichthyosis, Netherton Syndrome, or other ichthyosis subtypes will be enrolled.
Healthy control subjects will be enrolled for either a blood sample or skin sample, and/or tape strip samples.
Paller, AmyPaller, Amy
  • Map it 1131 Techny Rd.
    Northbrook, IL
  • Map it 225 E. Chicago Ave.
    Chicago, IL
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00203051
More Info

For more information on this study please contact us:

Patel, Krishna 312 227 6486
Joint Complaints in Children with Harlequin Ichthyosis: A Study to Assess for Comorbidity
The goal of this study is to understand the pattern of joint pain and what pain management options or treatments have worked for individuals with joint disease related to Harlequin Ichthyosis (HI). Participatio…
The goal of this study is to understand the pattern of joint pain and what pain management options or treatments have worked for individuals with joint disease related to Harlequin Ichthyosis (HI). Participation in the study will involve completing a one-time survey administered through letter mailing, emailing, link using an online survey, or in person at the Lurie Children’s Dermatology Clinic. The survey will take about 15-30 minutes.
Confirmed diagnosis of Harlequin Ichthyosis (HI) and have complaints of joint pain, difficulty walking, swelling or other similar issues with your muscles and bones.
Paller, AmyPaller, Amy
  • Map it 1131 Techny Rd.
    Northbrook, IL
  • Map it 225 E. Chicago Ave.
    Chicago, IL
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00203185
More Info

For more information on this study please contact us:

Murphrey, Morgan 312 503 5917
Defining The Skin and Blood Biomarkers of Pediatric Atopic Dermatitis
Atopic dermatitis (AD), also called eczema, is a disease in which the skin is dry and scaly with severe itching that may continue despite treatment. A deeper understanding of this disease is required to develop new and better treat…
Atopic dermatitis (AD), also called eczema, is a disease in which the skin is dry and scaly with severe itching that may continue despite treatment. A deeper understanding of this disease is required to develop new and better treatments. There are different types of cells and cell-produced signals (biomarkers) that have been found in adults with AD. Nevertheless, there may be significant differences between AD in children versus adults. The purpose of this study is to determine which blood and skin biomarkers characterize AD in children by looking at the blood and skin biomarkers of children with AD and children without AD.
This study will enroll children ages 0 months to 17 years to collect blood, skin, saliva and tape strip samples in order to look at biomarkers related to AD. Children who have or have not been diagnosed with AD or an atopic condition, such as allergies or asthma.
Paller, AmyPaller, Amy
  • Map it 1131 Techny Rd.
    Northbrook, IL
  • Map it 225 E. Chicago Ave.
    Chicago, IL
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00203272
More Info

For more information on this study please contact us:

Patel, Krishna 312 227 6486
A Double Blind, Randomized, Vehicle Controlled, Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients with the Mycosis Fungoides (MF) Form of Cutaneous T-Cell Lymphoma (CTCL)
The main goal of this study is to test the …
The main goal of this study is to test the efficacy and safety of topical Naloxone for itching in patients with MF.
21 years of age or older with a diagnosis of mycosis fungoides (MF) with itching present on a daily basis for more than one month and willing to fill out a diary for 7 days to provide severity of itch before enrollment.
Guitart, JoanGuitart, Joan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02811783 STU00203078
More Info

For more information on this study please contact us:

Serrano, Linda 312 503 5903
A Pilot Study to Evaluate the Efficacy and Safety of Secukinumab in the Treatment of Patients with Ichthyoses Sub-Study: A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Maintenance Dosing Period to Evaluate the Efficacy and Safety of Secukinumab in Patients with Ichthyoses
This is a year-long study which will require monthly visits to the study site. The first four months will be double blind (you may receive either the study medication or placebo), then the remainder of the year participants will receive monthly injections of study medication.
Participants must be 18 years of age or older, with a confirmed diagnosis of Autosomal Recessive Congential Ichthyosis (Lamellar Ichthyosis, Congential Ichthyosiform Erythroderma), Epidermolytic Ichthyosis, or Netherton's Syndrome, and at least moderate redness of the skin.
Paller, AmyPaller, Amy
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03041038 STU00202022
More Info

For more information on this study please contact us:

Wu, Benedict 312 503 5907
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Advanced Cutaneous Squamous Cell Carcinoma
The purpose of this study is to test the effects of REGN2810 in patients with advanced cutaneous squamous cell carcinoma (CSCC). The researchers wil…
The purpose of this study is to test the effects of REGN2810 in patients with advanced cutaneous squamous cell carcinoma (CSCC). The researchers will study the effects of REGN2810 and how long the effects last. The information will help researchers understand if REGN2810 could be used for the treatment of advanced CSCC. REGN2810 is an investigational drug. “Investigational” means that it is not approved by the US Food and Drug Administration (FDA).
Patients with unresectable locally advanced cutaneous squamous cell carcinoma (CSCC). Patients are required to have disease that is considered inoperable or to have medical contraindication to surgery or radiation, or have not achieved disease control with these treatments.
Alam, MuradAlam, Murad
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02760498 STU00202715
More Info

For more information on this study please contact us:

Wu, Benedict 312 503 5907
A Randomized Phase II Study of Topical Steroids as Preemptive Therapy for Epidermal Growth Factor Receptor Inhibitor-Induced Papulopustular Eruption
EGFR inhibitors are biologic agents used to treat certain cancers including non-small cell lung, colorectal, head and neck, and pancreatic carcinomas. T…
EGFR inhibitors are biologic agents used to treat certain cancers including non-small cell lung, colorectal, head and neck, and pancreatic carcinomas. These agents often have a side effect of an acne like rash that in some cases can be quite severe. This rash has been shown to be inflammatory in origin but is currently treated with antibiotics if it appears. The main goal of this study is to test if patients treated with steroid cream, (added) which is an anti-inflammatory medication, (added) before a rash develops have a less severe rash than patients who do not use a steroid cream before a rash develops.
Must be 18 years of age or older with a diagnosis of cancer and starting an (changed from 'and') EGFR inhibitor. During the study you must be willing to fill out a daily diary, use sunscreen and cream daily, and fill out 2 questionnaires and have photographs taken every 2 weeks for 4 visits.
Choi, JenniferChoi, Jennifer
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03115567 STU00203631
More Info

For more information on this study please contact us:

Serrano, Linda 312 503 5903
A Randomized, Bilateral Comparison, Vehicle-Controlled, Safety and Tolerability Study of Topical PAT-001 for the Treatment of Congenital Ichthyosis
Congenital ichthyosis is a large and varied family of inherited skin disorders characterized by dry, scaling skin that may be thickened or very thin. Thi…
Congenital ichthyosis is a large and varied family of inherited skin disorders characterized by dry, scaling skin that may be thickened or very thin. This clinical trial seeks to investigate the safety and tolerability of a topically applied ointment (PAT-001) as a treatment for congenital ichthyosis
Subjects must be at least twelve years old with clinically confirmed diagnosis of either lamellar ichthyosis or X-linked ichthyosis
Paller, AmyPaller, Amy
  • Map it 1131 Techny Rd.
    Northbrook, IL
  • Map it 225 E. Chicago Ave.
    Chicago, IL
NCT02864082 STU00204653
More Info

For more information on this study please contact us:

Patel, Krishna 312 227 6486
A Double-Blind, Randomized, Placebo Controlled, Parallel Dose Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata
Alopecia areata is an autoimmune disorder characterized by patches of non-scarring alopecia affecting scalp and body hair. This…
Alopecia areata is an autoimmune disorder characterized by patches of non-scarring alopecia affecting scalp and body hair. This research study will look at the investigational medication compared to a placebo when given to research subjects with alopecia areata twice-daily for a total of 24 weeks. The main purpose is to determine if the investigational medication causes hair to regrow, and to see if taking the investigational medication is safe. Other purposes of the study are to determine the amount of investigational medication in the blood after dosing, and to determine how you and your doctor feel about your alopecia areata during the study. The investigational medication is a modified version of another drug called Jakafi, which is approved by the FDA for other uses, but not for alopecia areata.
At least 50% hair loss on your head due to alopecia areata with a current episode of at least 6 months. You are required to be between the ages of 18 and 65 to participate in this study. You will not be able to participate if you are currently undergoing treatment with another drug or with other treatments that might affect your hair regrowth or if you are taking medicines that weaken your immune system.
Colavincenzo, Maria LColavincenzo, Maria L
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03137381 STU00204314
More Info

For more information on this study please contact us:

Orrell, Kelsey 312 503 5912
Corrona Psoriasis Registry
The main purpose of the Corrona Psoriasis registry is to learn more about psoriasis, how doctors treat psoriasis, how well medications and treatments work, and the safety of those treatments.
To be eligible, you need to be 18 years of age or older, have been diagnosed with psoriasis by a dermatologist, and have started on or switched to a systemic biologic psoriasis treatment within the previous 12 months by a Northwestern dermatologist.
Amin, AhmadAmin, Ahmad
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00203552
More Info
psoriasis

For more information on this study please contact us:

Thiede, Rebecca 312 503 5902
Gene Expression and Biomarker Profiling of Keloid Skin Sub-Study: A Pilot Trial of Keloid Genomic Profiling Using RNAseq
Northwestern’s Department of Dermatology is performing a research study to better understand the causes of keloid scars. Keloid scars are solid tissue overgrowths that tend to d…
Northwestern’s Department of Dermatology is performing a research study to better understand the causes of keloid scars. Keloid scars are solid tissue overgrowths that tend to develop after trauma to the skin.
Subjects who are 18 years of age or older. Have no history of keloids or have a keloid on the earlobe or on another area of your body that either has not been treated or if treated, the treatment took place more than 6 months ago.
Kundu, Roopal VashiKundu, Roopal Vashi
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03228693 STU00203462
More Info
keloid

For more information on this study please contact us:

Ali, Yasmeen 312 503 5906
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS).
Epidermolysis bullosa simplex (EBS) is a rare disorder that causes the skin to be…
Epidermolysis bullosa simplex (EBS) is a rare disorder that causes the skin to be fragile. It is passed down from one or both parents, and the main signs are painful blisters that can become infected. The purpose of this study is to assess the safety and efficacy of an investigational topical (applied to the skin) ointment called Diacerein 1% for people with EBS. Enrollment in the study can be for up to 22 weeks and it will involve about 8 study visits to the site.
At least 4 years of age with a clinical diagnosis and genetic mutation documented for epidermolysis bullosa simplex (EBS). Have EBS lesions that are greater than or equal to 2% body surface areas. The lesions need to be either generalized on the body or localized to the feet and palms. Patients with EBS lesions that are infected will be ineligible.
Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03154333 STU00205467
More Info

For more information on this study please contact us:

Zebda, Rema 312 227 6484
(CIRB) Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects with Moderate to Severe Atopic Dermatitis
This research is for subjects with moderate to severe atopic d…
This research is for subjects with moderate to severe atopic dermatitis, a skin condition also known as atopic eczema. The purpose of this study is to see how well subcutaneous doses of an the investigational drug or placebo works in possibly treating moderate to severe atopic dermatitis and to test its safety.
Between 18 -70 years of age with diagnosis of AD ≥ 2 years.
Silverberg, JonathanSilverberg, Jonathan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03055195 STU00204658
More Info

For more information on this study please contact us:

Orrell, Kelsey 312 503 5912
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients from 6 to Less than 18 Years of Age with Moderate-to-Severe Plaque Psoriasis
Plaque psoriasis is a condition in which skin cells build up and itchy, dry patches and…
Plaque psoriasis is a condition in which skin cells build up and itchy, dry patches and scales. The purpose of this study is to see how safe an investigational drug called ixekizumab for people with plaque psoriasis. This study is being done in two groups to understand how well ixekizumab will work to help people with plaque psoriasis. This study is also being done to get more information about the drug’s safety.
Between the ages of 6 and 18 years of age with a diagnosis of moderate-to-severe plaque-type psoriasis for at least 6 months.
Paller, AmyPaller, Amy
  • Map it 1131 Techny Rd.
    Northbrook, IL
  • Map it 225 E. Chicago Ave.
    Chicago, IL
NCT03073200 STU00205002
More Info

For more information on this study please contact us:

Patel, Krishna 312 227 6486
(xIRB) A Randomized, Double-Blind, Dose-Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo
Vitiligo is a condition in which pigment is lost from areas of the skin and results in whitish patches. This study will test the ability of a study drug to suppress the immune attack on the p…
Vitiligo is a condition in which pigment is lost from areas of the skin and results in whitish patches. This study will test the ability of a study drug to suppress the immune attack on the pigment producing cells in the skin and observe whether the pigment (normal skin color) in the skin can recover. The total duration of study participation is up to 120 weeks, which includes screening, three treatment parts, and safety follow‐up.
Diagnosed with Vitiligo by a dermatologist, between 18‐75 years of age, not currently on any light treatment, never used bleaching therapies in the past, and have de‐pigmented areas present on the face and non‐facial areas.
Kundu, Roopal VashiKundu, Roopal Vashi
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03099304 STU00204998
More Info

For more information on this study please contact us:

Thiede, Rebecca 312 503 5902
Comparison of the efficacy between Cryolipolysis versus ATX-101 (Deoxycholic acid) for the treatment of upper back fat: a prospective randomized controlled pilot study
The purpose of this study is to compare the effectiveness of cryolipolysis and ATX-101 (Deoxycholic acid)for the treatment of upper b…
The purpose of this study is to compare the effectiveness of cryolipolysis and ATX-101 (Deoxycholic acid)for the treatment of upper back fat. Cryolipolysis, also known as fat freezing, is the treatment used to destroy fat cells by cooling the skin causing cell death of fat tissue without damaging overlying skin. ATX-101 an injectable that can destroy fat cells.
Patients with mild to moderate upper back fat and currently living in the Chicago metropolitan area.
Alam, MuradAlam, Murad
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03284034 STU00205070
More Info

For more information on this study please contact us:

Weil, Alexandra 312 695 6785
A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF SERLOPITANT FOR THE TREATMENT OF PRURITUS IN ADULTS AND ADOLESCENTS WITH A HISTORY OF ATOPIC DERMATITIS
Atopic dermatitis (AD), commonly known as eczema, and have severe itching of the skin (aka “prurit…
Atopic dermatitis (AD), commonly known as eczema, and have severe itching of the skin (aka “pruritus”). Pruritus, or itch, is an unpleasant sensation in the skin that causes people the desire to scratch. The purpose of this study is to test the safety and effectiveness of oral serlopitant for the treatment of pruritus for people who have AD. Subjects in this study will be randomized to one of three groups (serlopitant high dose, serlopitant low dose, or placebo) to see whether the study agent reduces the amount or severity of pruritus for people with a history of AD.
Adults and adolescents (13 years and older) with history of atopic dermatitis who have severe pruritus despite treatment with standard of care anti-pruritic therapies.
Silverberg, JonathanSilverberg, Jonathan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02975206 STU00204970
More Info

For more information on this study please contact us:

Orrell, Kelsey 312 503 5912
Longitudinal Trial to Understand Symptomatology in Prurigo Nodularis (Chronic Prurigo)
Prurigo Nodularis (PN), is also known as Chronic Prurigo. PN is a skin disease with itchy nodules (bumps) which usually appear on the arms or legs. The purpose of the study is to learn more about PN, which means y…
Prurigo Nodularis (PN), is also known as Chronic Prurigo. PN is a skin disease with itchy nodules (bumps) which usually appear on the arms or legs. The purpose of the study is to learn more about PN, which means your health is observed over time in order to collect information on your condition and medicines you are currently taking as part of your routine care for your condition. The results of this study may help guide the development of new medications by gathering information about your symptoms and quality of life and how they are affected by PN and the treatment you receive.
Adult males and females >18 years of age, with a diagnosis of prurigo nodularis may be eligible to participate.
Silverberg, JonathanSilverberg, Jonathan
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00205363
More Info

For more information on this study please contact us:

Orrell, Kelsey 312 503 5912
(xIRB) A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects with Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
Cutaneous lupus erythematosus (CLE) is a chronic autoimmune disorder, most commonl…
Cutaneous lupus erythematosus (CLE) is a chronic autoimmune disorder, most commonly diagnosed in women 20-50 years of age. In CLE, the body’s immune system attacks the skin and causes rash and lesions (sores). This study will test an two experimental drugs called GS-9876 and filgotinib as a comparison drug for the treatment of CLE and a placebo. The subjects in this study will be randomly selected to enter into one of the three groups- those receiving GS-9876, filgotinib, or placebo. The purpose of this study is to see if filgotinib and/or GS-9876 are safe and effective for the treatment of your CLE.
Females ≥18 to ≤ 75 years with a diagnosis of Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE).
Laumann, Anne ELaumann, Anne E
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03134222 STU00205137
More Info

For more information on this study please contact us:

Orrell, Kelsey 312 503 5912
A randomized, double-blind, multi-center, parallel-group, placebo-controlled dose-ranging study to assess the efficacy and safety of nemolizumab (CD14152) in moderate-to-severe atopic dermatitis subjects with severe pruritus receiving topical corticosteroids.
Atopic dermatitis (AD) is a chronic infla…
Atopic dermatitis (AD) is a chronic inflammatory skin disease. In AD, the skin becomes very itchy, dry and inflamed, causing redness, swelling, cracking, crusting, and scaling. Scratching is believed to make the rash of AD worse, which will in turn cause more intensive itching and more scratching. In this study, subcutaneous doses of nemolizumab will be tested as a new treatment for AD in patients who are not sufficiently treated by existing topical treatments and who have severe itching.
Male or female subjects ≥18 years with a diagnosis of chronic Atopic Dermatitis for at least 2 years.
Silverberg, JonathanSilverberg, Jonathan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03100344 STU00205383
More Info

For more information on this study please contact us:

Orrell, Kelsey 312 503 5912
A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects with Moderate to Severe Plaque Psoriasis
Apremilast (also called Otezla) is approved for the treatment of Moderate to Severe Plaque Psoriasis and Psoriatic A…
Apremilast (also called Otezla) is approved for the treatment of Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis in adults in the United States (US), Canada, European Union (EU), Switzerland, Australia and Israel. Apremilast is not yet approved for use in children.
Patients ages 6 and 7 years old with moderate to severe plaque psoriasis
Paller, AmyPaller, Amy
  • Map it 1131 Techny Rd.
    Northbrook, IL
  • Map it 225 E. Chicago Ave.
    Chicago, IL
NCT02576678 STU00205963
More Info

For more information on this study please contact us:

Yousif, Rame 312 503 5944
Tralokinumab monotherapy for moderate to severe atopic dermatitis.
The purpose of the trial is to test if subcutaneous doses of the trial drug, tralokinumab, is better than placebo at treating moderate to severe atopic dermatitis, which will be judged by a range of assessments that rate the severity …
The purpose of the trial is to test if subcutaneous doses of the trial drug, tralokinumab, is better than placebo at treating moderate to severe atopic dermatitis, which will be judged by a range of assessments that rate the severity and extent of atopic dermatitis, itch and several other symptoms, as well as general health status and quality of life.
Ages 18 and above with moderate to severe Atopic dermatitis and with diagnosis of AD≥1 year.
Silverberg, JonathanSilverberg, Jonathan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03160885 STU00205339
More Info

For more information on this study please contact us:

Orrell, Kelsey 312 503 5912